|
Jan 19
|
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
|
|
Jan 19
|
Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?
|
|
Jan 18
|
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
|
|
Jan 16
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
Jan 16
|
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn’t One.
|
|
Jan 16
|
Trending tickers: Apple | Tesla | AstraZeneca | Hugo Boss
|
|
Jan 15
|
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca
|
|
Jan 12
|
Astrazeneca (AZN) Laps the Stock Market: Here's Why
|
|
Jan 12
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Jan 11
|
Here's Why Astrazeneca (AZN) Fell More Than Broader Market
|
|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Jan 4
|
Why the Market Dipped But Astrazeneca (AZN) Gained Today
|
|
Jan 2
|
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
|
|
Jan 2
|
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
|
|
Dec 29
|
Biotech Stocks Were Tanking. The Cure? M&A.
|
|
Dec 29
|
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
|
|
Dec 29
|
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
|
|
Dec 28
|
Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.
|
|
Dec 27
|
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Dec 27
|
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
|